Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06342310Phase 2Completed

RE104 Safety and Efficacy Study in Postpartum Depression

Role: lead

NCT07002034Phase 2Recruiting

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Role: lead

NCT07489651Phase 2Not Yet Recruiting

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

Role: lead

NCT07146191Phase 1Completed

RE104 Radiolabeled Mass Balance (hAME) Study

Role: lead

NCT06659263Phase 1Completed

RE104 Clinical Lactation Study

Role: lead

All 5 trials loaded